We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

220 hedge funds and large institutions have $4.68B invested in Blueprint Medicines in 2019 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 94 increasing their positions, 46 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

104% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 46

59% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 34

59% more call options, than puts

Call options by funds: $63.8M | Put options by funds: $40.2M

20% more capital invested

Capital invested by funds: $3.89B → $4.68B (+$792M)

8% more funds holding

Funds holding: 203 → 220 (+17)

8.55% less ownership

Funds ownership: 110.07% → 101.52% (-8.5%)

27% less funds holding in top 10

Funds holding in top 10: 11 → 8 (-3)

Holders
220
Holders Change
+17
Holders Change %
+8.37%
% of All Funds
4.78%
Holding in Top 10
8
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-27.27%
% of All Funds
0.17%
New
54
Increased
94
Reduced
46
Closed
34
Calls
$63.8M
Puts
$40.2M
Net Calls
+$23.6M
Net Calls Change
+$25.6M

Top Buyers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
+$148M
2
BlackRock
BlackRock
New York
+$58.6M
3
HM
HealthCor Management
New York
+$31.6M
4
CCM
Cadian Capital Management
New York
+$26.7M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$26.6M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$77.2M
2
TGI
TRV GP II
Massachusetts
-$70.4M
3
MWNA
Marshall Wace North America
New York
-$21.1M
4
LCM
Laurion Capital Management
New York
-$21M
5
CH
CVI Holdings
Delaware
-$16M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAMU
26
Pictet Asset Management (UK)
United Kingdom
$43.5M -$9.31M -112,838 -20%
BI
27
BVF Inc
California
$41.3M -$10.5M -127,400 -23%
American Century Companies
28
American Century Companies
Missouri
$37.7M +$5.41M +65,488 +20%
DM
29
Deerfield Management
New York
$36.9M -$9.54M -115,611 -23%
HM
30
HealthCor Management
New York
$36.1M +$31.6M +382,504 New
Loomis, Sayles & Company
31
Loomis, Sayles & Company
Massachusetts
$35.4M +$371K +4,501 +1%
GTC
32
Ghost Tree Capital
New York
$35.4M +$11.1M +135,000 +56%
Goldman Sachs
33
Goldman Sachs
New York
$33.2M -$4.1M -49,729 -12%
CAM
34
Cormorant Asset Management
Massachusetts
$33M -$8.25M -100,000 -22%
Deutsche Bank
35
Deutsche Bank
Germany
$29.3M +$12.3M +148,811 +92%
RSCM
36
Rock Springs Capital Management
Maryland
$29M +$2.68M +32,500 +12%
Charles Schwab
37
Charles Schwab
California
$27M +$3.32M +40,225 +16%
Brown Advisory
38
Brown Advisory
Maryland
$25.9M +$3.05M +36,972 +16%
VOYA Investment Management
39
VOYA Investment Management
Georgia
$23.5M -$6.71M -81,321 -25%
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$22.6M +$12.4M +150,365 +169%
N
41
Nuveen
North Carolina
$21.2M +$17.6M +212,940 +1,857%
Two Sigma Investments
42
Two Sigma Investments
New York
$20.4M +$9.77M +118,313 +120%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$20.1M +$1.59M +19,206 +10%
Jennison Associates
44
Jennison Associates
New York
$17.7M -$30.8K -373 -0.2%
SSA
45
Schonfeld Strategic Advisors
New York
$13.5M +$1.77M +21,500 +18%
Federated Hermes
46
Federated Hermes
Pennsylvania
$13.5M +$11.8M +142,754 New
NHAS
47
Novo Holdings A/S
Denmark
$12.5M +$5.4M +65,409 +97%
UBS AM
48
UBS AM
Illinois
$12.5M +$161K +1,953 +2%
OM
49
Opaleye Management
Massachusetts
$11.8M -$413K -5,000 -4%
Alkeon Capital Management
50
Alkeon Capital Management
New York
$11.8M – – –
1
2
3 4 5

BPMC Hedge Fund Activity: Q2 2019 in Review

220 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q2 2019, worth a combined $4.68B — up 20% from $3.89B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new BPMC positions and 34 closed out — a net gain of 20 holders — while 94 added to existing stakes and 46 trimmed.

The largest buyer was Invesco, adding an estimated $148M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $77.2M sold.

  • 220 institutional investors held Blueprint Medicines (BPMC) as of Q2 2019, up from 203 in Q1 2019.
  • Funds reported $4.68B of Blueprint Medicines stock for Q2 2019, up 20% quarter-over-quarter.
  • 54 funds opened new Blueprint Medicines positions in Q2 2019 and 34 closed out, a net change of +20 holders.
  • The largest Blueprint Medicines buyer in Q2 2019 was Invesco, an estimated $148M added.
  • The largest Blueprint Medicines seller in Q2 2019 was PFM Health Sciences, an estimated $77.2M sold.

Based on aggregated 13F filings for Q2 2019.